Table 2 Secondary endpoints in LATITUDE for the treatment and the placebo group
From: Management of Metastatic Castration-Naïve Prostate Cancer
Endpoint | ADT + AA/P (n = 597) | ADT + placebo (n = 602) | HR (95% CI) | p |
|---|---|---|---|---|
Median time to pain progression | NR | 16.6 months | 0.70 (0.58–0.83) | <0.001 |
Median time to PSA progression | 33.2 months | 7.4 months | 0.30 (0.26–0.35) | <0.001 |
Median time to symptomatic SRE | NR | NR | 0.70 (0.54–0.92) | 0.009 |
Median time to chemotherapy | NR | 38.9 months | 0.44 (0.35–0.56) | <0.001 |
Median time to next PCA-specific therapy | NR | 21.8 months | 0.42 (0.35–0.50) | <0.001 |
Patients with PSA responsea | 91% | 67% | 1.36 (1.28–1.45) | <0.001 |